Obermatt
See Similar Stocks →

Flags

Financial distress

Amicus Therapeutics

NMQ:FOLD · US03152W1099
BiotechnologyMedium

360° View

48
Price/Sales60
Price/Earnings7
Price/Book9
Dividend Yield1
Revenue Growth64
Profit Growth84
Capital Growth50
TSR 52w66
Leverage22
Liquidity72
Refinancing89
Combined47
Analyst Opinions1
Pro Holdings1
Opinion Changes50
Market Pulse69

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePrivate Company
ExchangeNASDAQGM
Founded2002
Employees632
Websiteamicusrx.com
ISINUS03152W1099
Last UpdateApr 2, 2026
Index & Theme
NephrologyGeneticsGenetic DisorderBiotechnologyHealth CarePharmaceutical

Description

Amicus Therapeutics, Inc. (Amicus) is a global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases. The company strives to redefine expectations in rare disea…

Analysis

Amicus Therapeutics's 360° View rank of 48 places it below its peer average — better than 48% of its true peers.

It's a growth standout (90) and expensive versus peers (4). On safety it is financially sound (70), and the market shows muted sentiment (35). Taken together, its Combined rank of 47 reads as below its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
60
—
—
—
Price/Earnings
7
—
—
—
Price/Book
9
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
4
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Amicus Therapeutics with its peers
Gilead
NSQ:GILD
67
CountryUSA
IndustryBiotechnology
SizeXX-Large
Full Stock Analysis →
Dyne Therapeutics
NSQ:DYN
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
PepGen
NSQ:PEPG
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sangamo Therapeutics
NAQ:SGMO
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tenaya Therapeutics
NSQ:TNYA
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →